Novartis receives positive CHMP opinion for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polyps

  • If approved, Xolair® (omalizumab) will provide patients who have severe chronic rhinosinusitis with nasal polyps, not adequately controlled by intranasal corticosteroids, with the first anti-immunoglobulin E (IgE) antibody specifically designed to target and block IgE, a key driver in the inflammatory pathway
     
  • Decision based on results from the Phase III POLYP 1 and 2 studies, in which omalizumab* significantly reduced the size of nasal polyps (defined by Nasal Polyp Score) and improved nasal congestion (defined by Nasal Congestion Score …
/by

Novartis Resolves Legacy FCPA Investigations

Basel, June 25, 2020 – Novartis has reached settlements with the US Department of Justice (DOJ) and the US Securities and Exchange Commission (SEC) resolving all Foreign Corrupt Practices Act (FCPA) investigations into historical conduct by the Company and its subsidiaries. As part of the settlements, Novartis and certain of its current and former subsidiaries will pay USD 233.9 million to the DOJ and USD 112.8 million to the SEC.

To resolve the DOJ investigation, Novartis Hellas S.A.C.I. has entered into a deferred prosecution agreement (“Novartis Hellas DPA …

/by

Novartis announces winners of the Innovation Prize for Assistive Tech, rewarding new technologies that could improve mobility and independence of people living with multiple sclerosis

  • The Novartis Innovation Prize: Assistive Tech for Multiple Sclerosis (MS) was initiated in 2019 as part of a commitment to innovation in Neuroscience to identify and encourage technology ideas from all over the world with the aim to improve mobility, accessibility and daily life for people living with MS
     
  • Canadian company AccessNow receives the first prize worth USD 250,000 for a mobile app and web platform that provides information about the accessibility status for people with disabilities of locations around the world, …
/by

Novartis research shows technology talent increasingly drawn to pharma industry since COVID-19, to solve healthcare challenges

    • 83% of technology (tech) professionals would consider working in healthcare and pharma, with 72% more likely to consider it compared to six months ago
       
    • 86% of tech professionals agree: the healthcare and pharma industry’s “digital moment” has arrived
       
    • Healthcare and pharma more than twice as attractive as traditional careers in financial services, telecoms and manufacturing
       
    • Report includes insights from Microsoft, MIT and Benevolent AI on the powerful pairing of …
/by

Novartis research shows technology talent increasingly drawn to pharma industry since COVID-19

On Wednesday June 24, 2020, Novartis revealed the healthcare and pharma industry has emerged as a desired career destination for tech talent during the COVID-19 pandemic, in the Powerful Pairing research report launched today. The report, which includes insights from Microsoft, MIT and Benevolent AI highlights:

  • 83% of tech professionals would consider working in healthcare and pharma, with 72% more likely to consider it compared to six months ago
  • 86% of tech professionals agree: the healthcare and pharma industry’s “digital moment” has arrived
  • Healthcare and …
/by

Novartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts

  • Study discontinued due to feasibility of recruitment; no safety issues have been reported or efficacy conclusions made
     
  • Novartis remains committed to ongoing research and development for COVID-19
     
  • Supply of hydroxychloroquine (HCQ) from Novartis will continue for clinical trials and upon government requests worldwide

Basel, June 19, 2020 — Novartis has made the decision to stop and discontinue its sponsored HCQ clinical trial for COVID-19 due to acute enrollment challenges that have made …

/by

Novartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts

 

  • Study discontinued due to feasibility of recruitment; no safety issues have been reported or efficacy conclusions made

 

  • Novartis remains committed to ongoing research and development for COVID-19

 

  • Supply of hydroxychloroquine (HCQ) from Novartis will continue for clinical trials and upon government requests worldwide

 

Basel, June 19, 2020 — Novartis has made the decision to stop and …

/by

Streamlining systems to respond to COVID-19

When the coronavirus pandemic broke out, Paul Aliu knew that he would have to act fast. His team at Novartis soon received a deluge of requests from physicians around the world. Doctors asked to access the company’s medicines more than 1 000 times during the first two months of the crisis to help patients with COVID-19 disease.

…
/by

World Sickle Cell Day 2020

As the world grapples with the COVID-19 pandemic, we need to continue our efforts to support vulnerable populations, who may be more at risk, such as people with sickle cell disease (SCD).

Sickle cell disease is a hereditary and life-threatening condition that causes ongoing vascular damage and repeated injury to the blood vessels and organs, including the heart and lungs. This lifelong illness often takes an extreme emotional, physical, and financial toll on patients and their families.

A holistic …

/by

Novartis expands Africa Sickle Cell Disease program to Uganda and Tanzania

  • New collaborations aim to reduce the burden of sickle cell disease (SCD) in East Africa and improve access to high quality care
     
  • Program continues progress in Ghana with more than 2000 patients being treated with hydroxyurea in 11 treatment centers across the country
     
  • Novartis plans to roll the program out to a total of 10 African countries by 2022
     
  • Approximately 1 000 children in Africa are born with SCD every day and more than half will die before they reach the age of five1

    • …

/by